EXEL

SEC source: 0000939767-18-000186 · wf-form4_153481022676695.xml · derivative · entry 3

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 50,000 shares

Expires 2020-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 160,000 shares of Exelixis, Inc. common stock, became exercisable as to 50% of such stock option on July 20, 2015 upon the satisfaction of one of the two performance goals set by the Compensation Committee. On December 10, 2014, the Compensation Committee determined that the second performance goal for the option had not, and would not, be achieved, resulting in the Reporting Person forfeiting the remaining 50% of such stock option.

SEC source: 0000939767-18-000186 · wf-form4_153481022676695.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,288

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000184 · wf-form4_153454913151692.xml · derivative · entry 3

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-18-000184 · wf-form4_153454913151692.xml · nonDerivative · entry 2

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,850

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.50 to $19.52. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-18-000184 · wf-form4_153454913151692.xml · nonDerivative · entry 1

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · derivative · entry 7

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,333 shares

Expires 2019-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 100,000 shares of Exelixis, Inc. common stock, became exercisable as to 25,000 shares on February 26, 2010, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the original grant date (February 26, 2009). The option ceased vesting on July 15, 2010, in connection with the Reporting Person's resignation as President and Chief Executive Officer of Exelixis, Inc., at which time the option was exercisable as to as to 33,333 shares of Exelixis, Inc. common stock.

SEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · derivative · entry 6

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 75,000 shares

Expires 2018-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became exercisable as to 50,000 shares on December 16, 2009, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the original grant date (December 16, 2008). The option ceased vesting on July 15, 2010, in connection with the Reporting Person's resignation as President and Chief Executive Officer of Exelixis, Inc., at which time the option was exercisable as to as to 75,000 shares of Exelixis, Inc. common stock.

SEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · nonDerivative · entry 2

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,586,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · nonDerivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,553,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · derivative · entry 11

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 570,284

Underlying: Common Stock · 34,267 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option, representing the right to purchase a total of 1,125,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · nonDerivative · entry 6

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.90 to $20.95. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · nonDerivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,267

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · derivative · entry 10

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 604,551

Underlying: Common Stock · 100,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option, representing the right to purchase a total of 1,125,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · nonDerivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.95 to $21.15. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · derivative · entry 9

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 704,551

Underlying: Common Stock · 100,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option, representing the right to purchase a total of 1,125,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.22. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-18-000179 · wf-form4_153385768970246.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 125,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000176 · wf-form4_153377076228186.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,917

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.92 to $20.93. Reporting Person undertakes to provide Exelixis, Inc. any security holder of Exelixis, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

F2 · balance_after: Includes 67,602 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000174 · wf-form4_153333799764968.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2018-09-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.

SEC source: 0000939767-18-000174 · wf-form4_153333799764968.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,288

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-18-000174 · wf-form4_153333799764968.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000125 · wf-form4_153187313353161.xml · derivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2018-09-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option, representing the right to purchase a total of 450,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.

SEC source: 0000939767-18-000125 · wf-form4_153187313353161.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.98. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-18-000125 · wf-form4_153187313353161.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 125,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000123 · wf-form4_153066645574683.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 22,500 shares

Expires 2018-09-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.

SEC source: 0000939767-18-000123 · wf-form4_153066645574683.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,288

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.10 to $21.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-18-000123 · wf-form4_153066645574683.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000121 · wf-form4_153014472247040.xml · derivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 90,000 shares

Expires 2018-09-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option, representing the right to purchase a total of 450,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.

SEC source: 0000939767-18-000121 · wf-form4_153014472247040.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.40 to $20.00. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-18-000121 · wf-form4_153014472247040.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 125,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000115 · wf-form4_152789751433380.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 22,500 shares

Expires 2018-09-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.

SEC source: 0000939767-18-000115 · wf-form4_152789751433380.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,288

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.65 to $21.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-18-000115 · wf-form4_152789751433380.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000117 · wf-form4_152789763605681.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,450

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.56 to $20.84. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

F2 · balance_after: Includes 62,187 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000116 · wf-form4_152789757102712.xml · derivative · entry 5

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

Underlying: Common Stock · 3,500 shares

Expires 2019-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012.

SEC source: 0000939767-18-000116 · wf-form4_152789757102712.xml · derivative · entry 4

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires 2019-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009.

SEC source: 0000939767-18-000116 · wf-form4_152789757102712.xml · nonDerivative · entry 3

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,221

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.57 to $20.68. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

SEC source: 0000939767-18-000116 · wf-form4_152789757102712.xml · nonDerivative · entry 2

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-18-000116 · wf-form4_152789757102712.xml · nonDerivative · entry 1

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-18-000111 · wf-form4_152720827542405.xml · derivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,874

Underlying: Common Stock · 15,874 shares

Expires 2025-05-23

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000939767-18-000111 · wf-form4_152720827542405.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,781

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 24, 2019, subject to the Reporting Person's continuous service through such date.

F3 · balance_after: Includes 13,780 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000110 · wf-form4_152720822079492.xml · derivative · entry 1

Smith Julie · CIK 0001557928 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,167

Underlying: Common Stock · 31,167 shares

Expires 2025-05-23

F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000939767-18-000109 · wf-form4_152720813374361.xml · derivative · entry 2

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,874

Underlying: Common Stock · 15,874 shares

Expires 2025-05-23

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000939767-18-000109 · wf-form4_152720813374361.xml · nonDerivative · entry 1

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,335

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 24, 2019, subject to the Reporting Person's continuous service through such date.

F3 · balance_after: Includes 13,780 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000108 · wf-form4_152720803868692.xml · derivative · entry 2

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,874

Underlying: Common Stock · 15,874 shares

Expires 2025-05-23

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000939767-18-000108 · wf-form4_152720803868692.xml · nonDerivative · entry 1

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,042,251

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 24, 2019, subject to the Reporting Person's continuous service through such date.

F3 · balance_after: Includes 13,780 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-18-000106 · wf-form4_152720783720964.xml · derivative · entry 2

WILLSEY LANCE · CIK 0001202106 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,167

Underlying: Common Stock · 31,167 shares

Expires 2025-05-23

F2 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000939767-18-000107 · wf-form4_152720794202244.xml · derivative · entry 2

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,874

Underlying: Common Stock · 15,874 shares

Expires 2025-05-23

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000939767-18-000107 · wf-form4_152720794202244.xml · nonDerivative · entry 1

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,850

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 24, 2019, subject to the Reporting Person's continuous service through such date.

F3 · balance_after: Includes 13,780 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.